New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
"His bone marrow transplant required a two-month inpatient stay where he wasn't able to step outside or feel fresh air," she ...
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...
KARACHI: Several essential medicines including advanced immunotherapy drugs used in cancer treatment, vaccines ...
The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.
Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...
Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic ...
The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.
Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...
If AML stops responding to conventional intensive chemotherapy or comes back, the chances of a long-term cure decrease significantly," explains Prof ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results